Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function

Clinical Therapeutics

Volumn 26, Issue 3, 2004, Pages 390-398

  Gretler, Daniel D ^a   Guerciolini, Roberto ^a   Williams, Paul J ^b  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b Trials by Design   (United States)

Author keywords

Creatinine clearance; Dosing strategy; Glycoprotein IIb IIIa inhibitors; Pharmacodynamics; Pharmacokinetics; Plasma concentration; Renal function

Indexed keywords

EPTIFIBATIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; DRUG TOLERABILITY; ECCHYMOSIS; EPISTAXIS; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FUNCTION; LEG EDEMA; MALE; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; STEADY STATE; SYNCOPE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA;

EID: 1842689870     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90034-3     Document Type: Article

References (11)

1. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
2. Fintel DJ, Ledley GS. Management of patients with non-ST-segment elevation acute coronary syndromes: Insights from the PURSUIT trial. Clin Cardiol. 2000;23(Suppl 5):V1-V12.
3. The Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial [published correction appears in Lancet. 2001;357:1370]. Lancet. 2000;356:2037-2044.
4. O'Shea JC, Hafley GE, Greenberg S, et al, for the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) Investigators. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA. 2001;285:2468-2473.
5. O'Shea JC, Buller CE, Cantor WJ, et al, for the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) Investigators. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 2002;287:618-621.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
7. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation. 1997;96:1488-1494.
8. Ette EI, Ludden TM. Population pharmacokinetic modeling: The importance of informative graphics. Pharm Res. 1995;12:1845-1855.
9. Ette EI. Statistical graphics in pharmacokinetics and pharmacodynamics: A tutorial. Ann Pharmacother. 1998;32:818-828.
10. Integrilin® (eptifibatide) [package insert]. 9th rev. Cambridge, Mass: Millennium Pharmaceuticals, Inc.; and Kenilworth, NJ: Schering-Plough Corporation; 2003.
11. Al Suwaidi J, Reddan DN, Williams K, et al, for the GUSTO-IIb, GUSTO-III, PURSUIT. Global Use of Strategies to Open Occluded Coronary Arteries. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy; PARAGON-A Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002;106:974-980.